CINCINNATI, Ohio — Anemia and vascular disorder drugmaker Akebia Therapeutics has named Ian A. W. Howes, the former chief financial officer at Serenex, its CFO and vice president of development (pdf).
Serenex was a lung-cancer drugmaker that was purchased by Pfizer about a year ago and raised a total of $81 million in venture capital. Akebia stated it wants Howes to help expand its pipeline of drugs. Along with anemia and vascular treatments, the company is also developing wound healing and cancer therapies.
Akebia expects in July to file an Investigational New Drug application for AKB-6548, an oral medication designed to create new red blood cells in anemia patients. Akebia raised $15.1 million (pdf) in December in part to start that drug on a Phase I trial this year.
“We have a number of very exciting programs underway and Ian’s experience in capital management, corporate development and operations will be essential in helping the company successfully move into our next phase of value creation,” Dr. Joseph Gardner, president and chief executive officer at Akebia, stated in the company’s release.
Radiology group Radisphere pulls in $10M in equity
Is the early stage funding valley of death a myth?
CWRU researchers: Drug shows promise in reducing Alzheimer’s plaque in brain
Sign up for MedCity News' e-newsletter, providing medical industry news from across the country.
Sign up
Anyone can blog on MedCity News when they become a "MedCitizen." MedCitizens publish their own thoughts about current medical news and the latest issues in healthcare to the entire MedCity News audience.
Amy SiegelHow low can you go? Creating value with cheap medical devices
Steven M. Auvil (Sponsored)5 things med tech companies need to know about the Leahy-Smith America Invents Act
Jim TateEscape Hatch for Electronic Submission of CQMs for Meaningful Use
Lisa Suennen2012 JP Morgan Healthcare’s (wo)men’s club is changing in a good way
Joe HageA huge American opportunity waiting to happen
Doug MowenMed tech consolidation brings a need for focus. Here are 2 ways to get it
Comments
Post a comment
[...] additional funding follows the company’s decision late last month to hire Ian Howes as its new chief financial officer and vice president of corporate development to expand drug [...]
Comment by Cardiovascular biopharma Akebia takes addition funding to develop 2 drugs : MedCity News — July 29, 2009 @ 12:48 am
[...] been a fast five months for Akebia. The company added a new chief financial officer in May and then said it had raised $25 million — $10 million beyond what it had announced [...]
Comment by Cincinnati’s Akebia Therapeutics races (as safely as possible) toward new anemia treatment : MedCity News — October 14, 2009 @ 4:04 pm
Post a Comment